

**Extended Table 1. All Adverse Events at least possibly related to treatment**

	Grade of Adverse Event									
	1		2		3		4		5	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
<b>Hematologic Adverse Events</b>										
Blood and lymphatic system disorders										
Anemia	6	-10%	4	-7%	3	-5%	0	0%	0	0%
<b>Non-Hematologic Adverse Events</b>										
Cardiac disorders										
Sinus tachycardia	1	-2%	0	0%	0	0%	0	0%	0	0%
Endocrine disorders										
Adrenal insufficiency	0	0%	1	-2%	0	0%	0	0%	0	0%
Eye disorders										
Uveitis	1	-2%	0	0%	0	0%	0	0%	0	0%
Gastrointestinal disorders										
Constipation	4	-7%	0	0%	0	0%	0	0%	0	0%
Diarrhea	3	-5%	0	0%	0	0%	0	0%	0	0%
Dry mouth	1	-2%	0	0%	0	0%	0	0%	0	0%
Mucositis oral	1	-2%	0	0%	0	0%	0	0%	0	0%
Nausea	4	-7%	0	0%	0	0%	0	0%	0	0%
Vomiting	2	-3%	0	0%	0	0%	0	0%	0	0%
General disorders and administration site conditions										
Chills	3	-5%	0	0%	0	0%	0	0%	0	0%
Edema face	1	-2%	0	0%	0	0%	0	0%	0	0%
Edema limbs	2	-3%	0	0%	0	0%	0	0%	0	0%
Fatigue	5	-8%	2	-3%	1	-2%	0	0%	0	0%
Fever	1	-2%	0	0%	0	0%	0	0%	0	0%
Injection site reaction	1	-2%	0	0%	0	0%	0	0%	0	0%
Localized edema	0	0%	1	-2%	0	0%	0	0%	0	0%
Malaise	1	-2%	0	0%	0	0%	0	0%	0	0%
Infections and infestations										
Lung infection	0	0%	1	-2%	0	0%	0	0%	0	0%
Injury, poisoning and procedural complications										
Infusion related reaction	1	-2%	1	-2%	0	0%	0	0%	0	0%
Investigations										
Alanine aminotransferase increased	6	-10%	1	-2%	0	0%	0	0%	0	0%
Alkaline phosphatase increased	8	-13%	0	0%	0	0%	0	0%	0	0%
Aspartate aminotransferase increased	2	-3%	1	-2%	1	-2%	0	0%	0	0%
Blood bilirubin increased	1	-2%	0	0%	0	0%	0	0%	0	0%
Creatinine increased	2	-3%	1	-2%	0	0%	0	0%	0	0%
Lymphocyte count decreased	0	0%	2	-3%	0	0%	0	0%	0	0%
Platelet count decreased	1	-2%	0	0%	0	0%	0	0%	0	0%
Thyroid stimulating hormone increased	1	-2%	0	0%	0	0%	0	0%	0	0%
Weight loss	1	-2%	0	0%	0	0%	0	0%	0	0%
White blood cell decreased	2	-3%	0	0%	0	0%	0	0%	0	0%
Metabolism and nutrition disorders										
Anorexia	2	-3%	0	0%	0	0%	0	0%	0	0%
Hyperkalemia	1	-2%	0	0%	0	0%	0	0%	0	0%

Hyponatremia	1	-2%	0	0%	0	0%	0	0%	0	0%
Metabolism and nutrition disorders - Other, specify	1	-2%	0	0%	0	0%	0	0%	0	0%
Musculoskeletal and connective tissue disorders										
Arthralgia	4	-7%	1	-2%	0	0%	0	0%	0	0%
Back pain	1	-2%	0	0%	0	0%	0	0%	0	0%
Generalized muscle weakness	0	0%	0	0%	1	-2%	0	0%	0	0%
Muscle cramp	2	-3%	0	0%	0	0%	0	0%	0	0%
Pain in extremity	1	-2%	0	0%	0	0%	0	0%	0	0%
Nervous system disorders										
Dizziness	2	-3%	0	0%	0	0%	0	0%	0	0%
Dysgeusia	2	-3%	0	0%	0	0%	0	0%	0	0%
Guillain-Barre syndrome	0	0%	0	0%	1	-2%	0	0%	0	0%
Headache	1	-2%	0	0%	0	0%	0	0%	0	0%
Nervous system disorders - Other, specify	0	0%	1	-2%	0	0%	0	0%	0	0%
Paresthesia	1	-2%	0	0%	0	0%	0	0%	0	0%
Peripheral sensory neuropathy	1	-2%	1	-2%	0	0%	0	0%	0	0%
Reproductive system and breast disorders										
Genital edema	1	-2%	0	0%	0	0%	0	0%	0	0%
Respiratory, thoracic and mediastinal disorders										
Allergic rhinitis	2	-3%	0	0%	0	0%	0	0%	0	0%
Cough	1	-2%	1	-2%	0	0%	0	0%	0	0%
Dyspnea	1	-2%	1	-2%	0	0%	0	0%	0	0%
Skin and subcutaneous tissue disorders										
Nail changes	1	-2%	0	0%	0	0%	0	0%	0	0%
Pruritus	3	-5%	0	0%	0	0%	0	0%	0	0%
Rash maculo-papular	5	-8%	0	0%	0	0%	0	0%	0	0%
Skin and subcutaneous tissue disorders - Other, specify	2	-3%	0	0%	0	0%	0	0%	0	0%
Skin hypopigmentation	1	-2%	0	0%	0	0%	0	0%	0	0%
Vascular disorders										
Hot flashes	2	-3%	0	0%	0	0%	0	0%	0	0%
Hypotension	0	0%	0	0%	1	-2%	0	0%	0	0%
<b>Non-Hematologic Adverse Events</b>										
Summary										
<b>Maximum Non-Hematologic AE</b>	<b>19</b>	<b>-32%</b>	<b>13</b>	<b>-22%</b>	<b>7</b>	<b>-12%</b>	<b>0</b>	<b>0%</b>	<b>0</b>	<b>0%</b>
<b>All Adverse Events</b>										
Summary										
<b>Maximum Overall AE</b>	<b>19</b>	<b>-32%</b>	<b>13</b>	<b>-22%</b>	<b>7</b>	<b>-12%</b>	<b>0</b>	<b>0%</b>	<b>0</b>	<b>0%</b>